Core Insights - The rapid growth of artificial intelligence (AI) is driving unprecedented demand for high-performance, secure, and innovative solutions in data centers [1] - Microchip Technology is developing advanced technologies to address evolving market needs in data center connectivity, storage, and data retrieval [1] Product Portfolio - Microchip's portfolio includes high-speed interconnect and storage technologies such as Gen 3, Gen 4, and Gen 5 PCIe switches, with Gen 6 and Gen 7 technologies in development [2] - The company offers Non-Volatile Memory Express (NVMe), storage and RAID controllers with hardware-based security for enhanced data protection [2] - Connectivity solutions include retimers and Ethernet PHYs to optimize interconnect functionality, along with power management and system monitoring solutions designed for energy-efficient operations [2] New Solutions - Introduction of the 800G Active Electrical Cable (AEC) Reference Design, featuring the META-DX2C 800G retimer with 112G SerDes, aimed at reducing development time and cost for generative AI networks [3][7] - The Lambda Splitting technique in the design significantly reduces costs and boosts bandwidth efficiency by up to 50% [7] - The LAN9646 6-Port Gigabit Ethernet (GbE) Switch supports multiple interface options and is designed for various networking applications, providing full VLAN and Quality of Service (QoS) support [7] Power Management - The MCPF1412 high-density power module delivers up to 12A of current within a voltage range of 0.6V to 1.8V, optimized for space-constrained applications [7] - dsPIC33A Digital Signal Controllers (DSCs) enhance energy efficiency and reliability in data centers and AI servers, with features for power factor correction and synchronous rectification [13] Security Features - Microchip's data center solutions include Secure Root of Trust Controllers that protect system integrity by verifying firmware at power-up and monitoring system activity [9] - These controllers support secure system ownership transfer and robust lifecycle management [9] Industry Commitment - The company emphasizes its commitment to delivering essential building blocks to address technology challenges in modern data centers, focusing on high-speed connectivity, storage rates, and power management systems [9]

PETAH TIKVA, Israel, April 28, 2025 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (NASDAQ, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, today announced management’s participation in the 20th Annual Needham Technology, Media and Consumer Conference at the the Intercontinental New York Times Square Hotel in New York City. Mr. Adi Sfadia, the Company’s CEO, and Mr. Gil Benyamini, the Company’s CFO, will be available for one-on-one meetings with investors on M ...

Compelling Phase 1 safety and efficacy data for FAP-Dox (AVA6000) with preliminary evidence of efficacy in salivary gland cancers and no severe cardiac toxicity Progression free survival (PFS) data to date represents a near doubling of the benchmarking data in this patient population without reaching median PFS LONDON and PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-t ...

Approval of Lynozyfic is based on data showing deep and durable responses in relapsed/refractory multiple myeloma Lynozyfic will provide a new option with convenient dosing and administration to patients who face cycles of relapse and remission TARRYTOWN, N.Y., April 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Commission (EC) has granted conditional marketing approval of Lynozyfic™ (linvoseltamab) to treat adults with relapsed and refractory ...

Core Insights - Roper Technologies, Inc. reported a strong start to 2025 with total revenue growth of 12%, driven by 8% from acquisitions and 5% organic growth [3][4] - The company has increased its full year guidance for 2025, expecting adjusted diluted earnings per share (DEPS) of $19.80 - $20.05, up from the previous range of $19.75 - $20.00 [4][5] - Roper completed the acquisition of CentralReach, enhancing its cloud-native software offerings for Applied Behavior Analysis therapy [3][5] Financial Performance - Total revenue for Q1 2025 was $1.88 billion, a 12% increase from $1.68 billion in Q1 2024, with organic revenue growth of 5% and acquisition contribution of 8% [8][10] - GAAP net earnings decreased by 13% to $331 million, while adjusted net earnings increased by 9% to $517 million [8][10] - Adjusted EBITDA rose by 9% to $740 million, with an adjusted EBITDA margin of 39.3% [8][10] Cash Flow and Capital Management - Trailing twelve-months free cash flow grew by 12% to $2.39 billion, with a free cash flow margin of 31% [3][8] - Operating cash flow for Q1 2025 was $529 million, a slight decrease of 1% compared to $531 million in Q1 2024 [12][26] - The company maintains a disciplined capital deployment strategy, supported by significant M&A capabilities and a robust pipeline of acquisition opportunities [3][4] Segment Performance - Application Software segment generated $1.07 billion in revenue, while Network Software and Technology Enabled Products segments contributed $375.9 million and $438.7 million, respectively [24] - Gross profit margins for Application Software, Network Software, and Technology Enabled Products were 67.5%, 84.0%, and 58.7%, respectively [24][25] Guidance and Outlook - Roper expects full year 2025 total revenue growth to be approximately 12%, up from a previous outlook of 10%+, with organic revenue growth anticipated at 6% - 7% [4][5] - For Q2 2025, the company projects adjusted DEPS of $4.80 - $4.84 [4][13]

Core Points - Eton Pharmaceuticals has submitted a New Drug Application (NDA) for ET-600, an oral solution of desmopressin for treating central diabetes insipidus, with a 10-month FDA review expected and a potential launch in Q1 2026 [1][2] - If approved, ET-600 will be the only FDA-approved oral liquid formulation of desmopressin, addressing the needs of approximately 3,000 pediatric patients in the U.S. [2] - Eton holds a patent for ET-600 that expires in 2044, with additional patent applications under review [2] - The company has seven commercial rare disease products and six additional product candidates in late-stage development [3]

Core Insights - Arvinas, Inc. presented promising preclinical data for ARV-393, a PROTAC BCL6 degrader, showing strong synergistic antitumor activity in combination with standard-of-care treatments for aggressive B-cell lymphomas [1][2][4] Group 1: Study Findings - ARV-393 demonstrated complete tumor regressions in high-grade B-cell lymphoma and aggressive diffuse large B-cell lymphoma models when combined with standard-of-care chemotherapy and biologics [1][4] - The combination of ARV-393 with R-CHOP chemotherapy resulted in significantly greater tumor growth inhibition compared to R-CHOP or ARV-393 alone, with complete regressions observed in all treated mice [4] - Combinations of ARV-393 with investigational small molecule inhibitors targeting oncogenic drivers like BTK, BCL2, and EZH2 also led to superior tumor growth inhibition and regressions in all treated mice [4] Group 2: Clinical Development - A Phase 1 clinical trial of ARV-393 is currently enrolling patients with relapsed/refractory non-Hodgkin lymphoma, including DLBCL [2][5] - The preclinical data support the potential for broad combinability of ARV-393, providing a rationale for further exploration of combination strategies in lymphoma treatment [2][5] Group 3: Company Overview - Arvinas is a clinical-stage biotechnology company focused on developing therapies based on targeted protein degradation, with a pipeline that includes ARV-393 for non-Hodgkin lymphoma and other investigational drugs for various conditions [6]

Core Viewpoint - Fingrid's financial performance in the first quarter of 2025 showed a decline in turnover compared to the previous year, but improvements in net cash flow and a strong financial position were noted, alongside significant developments in the electricity market and infrastructure [2][4][9]. Financial Performance - Turnover for January–March 2025 was €370.7 million, down 21.6% from €472.9 million in the same period of 2024 [3]. - Operating result was €119.5 million, slightly down from €119.8 million year-on-year [3]. - Result before taxes decreased to €115.9 million from €118.1 million [3]. - Net cash flow from operations surged to €220.8 million, a 502% increase from €36.7 million [3]. - The result for the period improved to €81.6 million from €64.9 million, marking a 25.7% increase [3]. Operational Highlights - Electricity consumption in Finland decreased to 23.8 TWh from 24.6 TWh, attributed to a mild winter [4][9]. - Fingrid's transmission accounted for 79.0% of Finland's total electricity consumption, transmitting 18.8 TWh [9]. - The system security rate remained high at 100% [3][4]. - Renewable production capacity connected to the main grid was 432 MW, down from 528 MW [3][9]. Market Developments - The transition to a 15-minute electricity market progressed, with the new market time unit introduced successfully in January and March [9]. - The Nordic mFRR energy action market was rolled out, experiencing significant price volatility [9]. - Fingrid's share of accrued congestion income was €71.4 million, down from €75.0 million [4]. Capital Expenditure and Investments - Fingrid estimates gross capital expenditure of approximately €1.7 billion from 2025 to 2028, with €623 million already committed [4]. - Capital expenditure for the first quarter was €93.0 million, up 20.8% from €77.0 million [3]. Legal and Regulatory Matters - Fingrid has appealed against the Energy Authority's decisions regarding balance service terms and profit specification methods for electricity transmission operations [11][12]. - Ongoing legal proceedings concern the connection of the Olkiluoto 3 nuclear power plant to the grid, with Fingrid asserting compliance with its obligations [13]. Governance and Leadership - The Annual General Meeting approved the financial statements for 2024 and decided on dividend distribution, with Eeva-Liisa Virkkunen elected as the new Chair of the Board [17].

Revenue increased 31% to $91 million, adjusted EBITDA increased 47% to $21 million, and sales pipeline more than doubles to $2 billionST. JOHN'S, Newfoundland and Labrador, April 28, 2025 (GLOBE NEWSWIRE) -- Kraken Robotics Inc. (TSX-V: PNG, OTCQB: KRKNF) (“Kraken” or the “Company”), announced it has filed its financial results for the fourth quarter and year ended December 31, 2024 (“Q4 2024”). Please refer to the Audited Consolidated Financial Statements, Management’s Discussion and Analysis (“MD&A”) and ...

LONGUEUIL, Québec, April 28, 2025 (GLOBE NEWSWIRE) -- Azimut Exploration Inc. (“Azimut” or the “Company”) (TSXV: AZM) (OTCQX: AZMTF) is pleased to announce that it has entered into a subscription agreement with Centerra Gold Inc. (“Centerra”) (TSX: CG) (NYSE: CGAU) for a non-brokered private placement of 9,430,000 common shares of the Company at a price of $0.60 per share for gross proceeds of $5,658,000 (the “Offering”). Centerra will become a strategic investor in the Company, acquiring approximately 9.9% ...